title: [Therapeutics of the future for allergy].
abstract: Future improvement in the therapeutic arsenal in allergy must in part be by improvement of the existing, by the development of new molecules that are more powerful and more selective amongst the antiH1, chromones, Beta-2 mimetics, corticoids as well as the development of new routes of already-know products. Specific Immunotherapy (ITS) will undoubtedly benefit from progress in geni-genetics, from improvement in adjuvants and development of new routes of administration. Control of the environment will assist industry for the manufacture of anti mite bedding and household materials. Primary prevention will be based on better identification of populations at risk and on rationalisation of the alimentary diversification of infants, so controlling the environment of populations at risk. Finally, better understanding of the complex interaction of cytokines will allow consideration of creation, following the recent example of antileukotrienes, of new products of intervention and in particular regulation of the TH1-TH2 balance.
authors.affiliation: Centre Hospitalier, Vitré.
authors.forename: G
authors.initials: G
authors.lastname: Sibille
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007167:Immunotherapy / Q000639:trends*; D011322:Primary Prevention / Q000639:trends*
chemical_list: D018926:Anti-Allergic Agents
vernacular_title: Thérapeutiques du futur en allergologie.